TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System
TriSalus Life Sciences (Nasdaq: TLSI) announced the publication of research in the Journal of Vascular and Interventional Radiology demonstrating improved delivery of glass microspheres to liver tumors using their Pressure Enabled Drug Delivery (PEDD) method via the TriNav Infusion System. The study, conducted on transgenic pigs with induced liver tumors, showed:
- 117% increase in tumor penetration with lobar infusions (p=0.004)
- 39% increase in tumor penetration with selective infusions (p=0.032)
- Lobar PEDD delivery was statistically equivalent to conventional selective delivery (p=0.497)
The research suggests that the PEDD method could potentially improve the efficacy and safety of liver cancer treatments by increasing the concentration of therapeutics in tumors compared to adjacent liver tissue.
TriSalus Life Sciences (Nasdaq: TLSI) ha annunciato la pubblicazione di una ricerca nel Journal of Vascular and Interventional Radiology che dimostra un miglioramento nella somministrazione di microsfere di vetro ai tumori epatici utilizzando il loro metodo di somministrazione di farmaci abilitato dalla pressione (PEDD) tramite il TriNav Infusion System. Lo studio, condotto su maiali transgenici con tumori epatici indotti, ha mostrato:
- Un aumento del 117% nella penetrazione tumorale con infusione lobare (p=0.004)
- Un aumento del 39% nella penetrazione tumorale con infusione selettiva (p=0.032)
- La somministrazione lobare con PEDD era statisticamente equivalente alla somministrazione selettiva convenzionale (p=0.497)
La ricerca suggerisce che il metodo PEDD potrebbe migliorare l'efficacia e la sicurezza dei trattamenti per il cancro al fegato aumentando la concentrazione dei farmaci nei tumori rispetto ai tessuti epatici adiacenti.
TriSalus Life Sciences (Nasdaq: TLSI) anunció la publicación de una investigación en el Journal of Vascular and Interventional Radiology que demuestra una mejora en la entrega de microsferas de vidrio a tumores hepáticos utilizando su método de entrega de fármacos habilitado por presión (PEDD) a través del TriNav Infusion System. El estudio, realizado en cerdos transgénicos con tumores hepáticos inducidos, mostró:
- Un aumento del 117% en la penetración tumoral con infusiones lobares (p=0.004)
- Un aumento del 39% en la penetración tumoral con infusiones selectivas (p=0.032)
- La entrega lobar con PEDD fue estadísticamente equivalente a la entrega selectiva convencional (p=0.497)
La investigación sugiere que el método PEDD podría mejorar potencialmente la eficacia y seguridad de los tratamientos contra el cáncer de hígado aumentando la concentración de terapéuticos en los tumores en comparación con el tejido hepático adyacente.
TriSalus Life Sciences (Nasdaq: TLSI)가 Journal of Vascular and Interventional Radiology에 발표한 연구 결과, TriNav Infusion System을 통해 Pressure Enabled Drug Delivery (PEDD) 방법을 사용하여 간 종양에 유리 미세구슬을 보다 효과적으로 전달하는 방법을 보여주었습니다. 이 연구는 유도된 간 종양을 가진 트랜스제닉 돼지에서 수행되었으며, 다음과 같은 결과를 보였습니다:
- 간엽 주입으로 117% 증가한 종양 침투율 (p=0.004)
- 선택적 주입으로 39% 증가한 종양 침투율 (p=0.032)
- 간엽 PEDD 전달은 기존 선택적 전달과 통계적으로 동등했습니다 (p=0.497)
이 연구는 PEDD 방법이 인접한 간 조직에 비해 종양 내 치료제의 농도를 증가시켜 간암 치료의 효율성과 안전성을 개선할 수 있음을 시사합니다.
TriSalus Life Sciences (Nasdaq: TLSI) a annoncé la publication d'une recherche dans le Journal of Vascular and Interventional Radiology démontrant une amélioration de la délivrance de microsphères de verre aux tumeurs du foie grâce à leur méthode de délivrance de médicaments activée par pression (PEDD) via le TriNav Infusion System. L'étude, réalisée sur des porcs transgéniques ayant des tumeurs hépatiques induites, a montré :
- Une augmentation de 117% de la pénétration tumorale avec des infusions lobaires (p=0.004)
- Une augmentation de 39% de la pénétration tumorale avec des infusions sélectives (p=0.032)
- La délivrance lobaire par PEDD était statistiquement équivalente à la délivrance sélective conventionnelle (p=0.497)
La recherche suggère que la méthode PEDD pourrait potentiellement améliorer l'efficacité et la sécurité des traitements du cancer du foie en augmentant la concentration des thérapeutiques dans les tumeurs par rapport aux tissus hépatiques adjacents.
TriSalus Life Sciences (Nasdaq: TLSI) gab die Veröffentlichung einer Forschung im Journal of Vascular and Interventional Radiology bekannt, die eine verbesserte Abgabe von Glasmikrosphären an Lebertumoren zeigt, die mit ihrer Pressure Enabled Drug Delivery (PEDD)-Methode über das TriNav Infusion System durchgeführt wurde. Die Studie, die an transgenen Schweinen mit induzierten Lebertumoren durchgeführt wurde, zeigte:
- Ein 117%iger Anstieg der Tumordurchdringung bei lobaren Infusionen (p=0.004)
- Ein 39%iger Anstieg der Tumordurchdringung bei selektiven Infusionen (p=0.032)
- Die lobare PEDD-Abgabe war statistisch gleichwertig zur konventionellen selektiven Abgabe (p=0.497)
Die Forschung legt nahe, dass die PEDD-Methode das Potenzial hat, die Wirksamkeit und Sicherheit von Leberkrebsbehandlungen zu verbessern, indem die Konzentration der Therapeutika in den Tumoren im Vergleich zum angrenzenden Lebergewebe erhöht wird.
- Significant increase in glass microsphere penetration into liver tumors using PEDD method
- Potential for improved efficacy and safety in liver cancer treatments
- PEDD method effective in both lobar and selective infusions
- Publication in a peer-reviewed journal validates the technology
- None.
Pressure enabled drug deliver (PEDD) method significantly increased penetration of glass microspheres into porcine liver tumors (
“This is another example of how our PEDD approach effectively tackles a significant challenge in cancer care by ensuring the selective and increased delivery of therapeutics to the tumor. This research advances and validates our understanding of the PEDD method, providing high-resolution evidence of enhanced delivery,” said Bryan F. Cox, Ph.D., Chief of Research for TriSalus. “With both proximal and distal placements of the PEDD device, we observed significantly improved delivery of glass microspheres to the tumor, quantified on a millimeter scale. The strength of the proximal infusion data suggests an opportunity to selectively target multiple tumors simultaneously in patients with heavy disease burdens.”
“These results contribute to the substantial and expanding body of pre-clinical and clinical evidence supporting the wide-ranging potential applicability of the PEDD approach,” said Mary Szela, Chief Executive Officer and President of TriSalus. “Efficient delivery of therapeutics into tumor cells without causing harm to off-target normal tissue remains a real-world challenge in cancer care, and the PEDD approach aims to overcome this obstacle. This publication strengthens our current understanding that, regardless of placement of the technology, either lobar or selective infusions, the PEDD method increased glass microspheres delivery uptake compared to conventional microcatheters. The TriNav device signifies a potential breakthrough in delivering glass microspheres and other drugs into tumors in a highly controlled and targeted manner.”
“This study shows the potential of PEDD method to address an unmet need in liver cancer therapy – achieving the same safety profile of selective
The research involved transgenic pigs (oncopigs) with induced liver tumors. These tumors were intra-arterially infused with fluorescently labeled GM. The PEDD method with the TriNav device was compared to the use of conventional microcatheter delivery in both lobar and selective infusions. Near-infrared (near IR) imaging was utilized to detect the GM fluorescent signal in tumors. The results showed significant increases in GM signal intensity in and around tumors after delivery with the PEDD method, with a
A copy of the full abstract can be accessed here.
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are commonly present as well. Nelitolimod delivered by PEDD will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X (formerly Twitter) and LinkedIn.
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “become,” “may,” “intend,” “will,” “expect,” “anticipate,” “believe” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements may include, but are not limited to, statements regarding the consummation of the Offer and Consent Solicitation, the timing of the Expiration Date, the future effectiveness of the registration statement on Form S-4, the approval by the holders of Warrants of the Warrant Amendment and subsequent entry into the Warrant Amendment, the effects of the Offer on our capital structure and expected changes to the dilutive impact of the Warrants. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including, without limitation: the Company’s ability to successfully complete the Offer and Consent Solicitation; the number of holders of Warrants that approve the Warrant Amendment in the Consent Solicitation; the timing and results of the SEC review of the registration statement on Form S-4 filed on May 24, 2024, if any; the Company’s ability to attract and retain customers and expand customers’ use of the Company’s products; risks relating to market, financial, political and legal conditions; risks relating to the uncertainty of the projected financial and operating information with respect to the Company; risks related to future market adoption of the Company’s offerings; risks related to the Company’s marketing and growth strategies; risks related to the Company’s ability to acquire or invest in businesses, products or technologies that may complement or expand its products, enhance its technical capabilities or otherwise offer growth opportunities; the effects of competition on the Company’s future business; the risks discussed in the Company’s quarterly report on Form 10-Q for the period ended March 31, 2024 under the heading “Risk Factors”; and the risks discussed in the Company’s Registration Statement on Form S-4 filed on May 24, 2024, under the heading “Risk Factors” and other documents of the Company filed, or to be filed, with the SEC. If any of these risks materialize or any of the Company’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently does not know of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by applicable law. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240919558761/en/
For Media Inquiries:
Stephanie Jacobson
Argot Partners
610.420.3049
TriSalus@argotpartners.com
For Investor Inquiries:
James Young
SVP-Investor Relations/Treasurer
847.337.0655
james.young@trisaluslifesci.com
Source: TriSalus Life Sciences
FAQ
What were the key findings of TriSalus' PEDD method study for TLSI stock?
How might the PEDD method impact liver cancer treatment for TLSI?
What animal model was used in TriSalus' PEDD method study for TLSI?